[HTML][HTML] Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells
Genetic alterations in BRAF, NRAS and NF1 that activate the ERK cascade, account for over
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells
R Arafeh, K Flores, A Keren-Paz… - Scientific …, 2017 - pubmed.ncbi.nlm.nih.gov
Genetic alterations in BRAF, NRAS and NF1 that activate the ERK cascade, account for over
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells
R Arafeh, K Flores, A Keren-Paz… - Scientific …, 2017 - ui.adsabs.harvard.edu
Genetic alterations in BRAF, NRAS and NF1 that activate the ERK cascade, account for over
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.
R Arafeh, K Flores, A Keren-Paz, G Maik-Rachline… - Scientific …, 2017 - europepmc.org
Genetic alterations in BRAF, NRAS and NF1 that activate the ERK cascade, account for over
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
[PDF][PDF] Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells
R Arafeh, K Flores, A Keren-Paz, G Maik-Rachline… - academia.edu
Results Effect of inhibition of nuclear ERK1/2 translocation by the EPE peptide on the
viability of metastatic melanoma cells. Previously, we have found that the EPE peptide …
viability of metastatic melanoma cells. Previously, we have found that the EPE peptide …
Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells
R Arafeh, K Flores, A Keren-Paz… - Scientific …, 2017 - pure.johnshopkins.edu
Genetic alterations in BRAF, NRAS and NF1 that activate the ERK cascade, account for over
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells
R Arafeh, K Flores, A Keren-Paz… - Scientific …, 2017 - weizmann.esploro.exlibrisgroup.com
Genetic alterations in BRAF, NRAS and NF1 that activate the ERK cascade, account for over
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
[引用][C] Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells
R Arafeh, K Flores, A Keren-Paz, G Maik-Rachline… - Scientific Reports, 2017 - cir.nii.ac.jp
Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor
activity in melanoma cells | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
activity in melanoma cells | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells
R Arafeh, K Flores, A Keren-Paz… - Scientific …, 2017 - weizmann.elsevierpure.com
Genetic alterations in BRAF, NRAS and NF1 that activate the ERK cascade, account for over
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
[HTML][HTML] Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells
R Arafeh, K Flores, A Keren-Paz… - Scientific …, 2017 - ncbi.nlm.nih.gov
Genetic alterations in BRAF, NRAS and NF1 that activate the ERK cascade, account for over
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …
80% of metastatic melanomas. However, ERK cascade inhibitors have been proven …